The pathophysiological mechanism between hypopituitarism and nonalcoholic fatty liver disease

Yeliosof O, Gangat M. Diagnosis and management of hypopituitarism. Curr Opin Pediatr 2019;31(4): 531–6.

Jasim S, Alahdab F, Ahmed AT, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine 2017;56(1): 33–42.

Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47): 8263–76.

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24(7): 908–22.

Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1): 11–20.

Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158(7): 1999–2014. e1.

Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40(9): 2082–9.

Yuan XX, Zhu HJ, Pan H, et al. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. World J Gastroenterol 2019; 25(14): 1741–52.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of nonalcoholic fatty liver disease (NAFLD). Metabolism 2016;65(8): 1038–48.

Fang YL, Chen H, Wang CL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from "two hit theory" to "multiple hit model. World J Gastroenterol 2018;24(27): 2974–83.

Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev 2017;49(2): 197–211.

Sliz E, Sebert S, Wurtz P, et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet 2018;27(12): 2214–23.

Abdelmegeed MA, Ha SK, Choi Y, et al. Role of CYP2E1 in mitochondrial dysfunction and hepatic injury by alcohol and non-alcoholic substances. Curr Mol Pharmacol 2017;10(3): 207–25.

Sinha RA, Bruinstroop E, Singh BK, et al. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid 2019;29(9): 1173–91.

Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014;94(2): 355–82.

Lugari S, Mantovani A, Nascimbeni F, et al. Hypothyroidism and nonalcoholic fatty liver disease - a chance association? Horm Mol Biol Clin Invest 2018;41(1).

Chung GE, Kim D, Kim W, et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012;57(1): 150–6.

Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci 2012;57(2): 528–34.

Mantovani A, Nascimbeni F, Lonardo A, et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Thyroid 2018;28(10): 1270–84.

Kim D, Kim W, Joo SK, et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol 2018;16(1): 123–131. e1.

Kim D, Yoo ER, Li AA, et al. Low-normal thyroid function is associated with advanced fibrosis among adults in the United States. Clin Gastroenterol Hepatol 2019;17(11): 2379–81.

Jaruvongvanich V, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is not associated with thyroid hormone levels and hypothyroidism: a systematic review and meta-analysis. Eur Thyroid J 2017;6(4): 208–15.

Martinez EA, Pera G, Arteaga I, et al. Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population. Med Clin 2020;154(1): 1–6.

Duntas LH, Brenta G. A renewed focus on the association between thyroid hormones and lipid metabolism. Front Endocrinol (Lausanne) 2018;9: 511.

Goldberg IJ, Huang LS, Huggins LA, et al. Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. Endocrinology 2012;153(11): 5143–9.

Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 2003;278(36): 34114–8.

Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res 2019;124(10): 1505–18.

Pedrelli M, Pramfalk C, Parini P. Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport. World J Gastroenterol 2010;16(47): 5958–64.

Babashamsi MM, Koukhaloo SZ, Halalkhor S, et al. ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity. Diabetes Metab Syndr 2019;13(2): 1529–34.

Huuskonen J, Vishnu M, Pullinger CR, et al. Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor. Biochemistry 2004; 43(6): 1626–32.

Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul) 2018;33(1): 33–43.

Chen Y, Wu X, Wu R, et al. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism. Sci Rep 2016;6: 26174.

Lee Y, Yu X, Gonzales F, et al. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A 2002; 99(18): 11848–53.

Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf) 1998;49(5): 583–8.

Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS- 3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004;24(12): 5434–46.

Rotundo L, Persaud A, Feurdean M, et al. The Association of leptin with severity of non-alcoholic fatty liver disease: a population-based study. Clin Mol Hepatol 2018; 24(4): 392–401.

La Cava A. Leptin in inflammation and autoimmunity. Cytokine 2017;98: 51–8.

Martinez-Una M, Lopez-Mancheno Y, Dieguez C, et al. Unraveling the role of leptin in liver function and its relationship with liver diseases. Int J Mol Sci 2020; 21(24).

Kar K, Sinha S. Variations of adipokines and insulin resistance in primary hypothyroidism. J Clin Diagn Res 2017;11(8): BC07–9.

Qiu Y, Wang SF, Yu C, et al. Association of circulating adipsin, visfatin, and adiponectin with nonalcoholic fatty liver disease in adults: a case-control study. Ann Nutr Metab 2019;74(1): 44–52.

Gierej P, Gierej B, Kalinowski P, et al. Expression of resistin in the liver of patients with non-alcoholic fatty liver disease. Pol J Pathol 2017;68(3): 225–33.

Klose M, Marina D, Hartoft-Nielsen ML, et al. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab 2013;98(9): 3802–10.

Gronich N, Deftereos SN, Lavi I, et al. Hypothyroidism is a risk factor for newonset diabetes: a cohort study. Diabetes Care 2015;38(9): 1657–64.

Moeller LC, Dumitrescu AM, Walker RL, et al. Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab 2005;90(2): 936–43.

Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160(5): 785–90.

Tomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci 2002;967: 43–51.

Tritos NA, Klibanski A. Effects of growth hormone on bone. Prog Mol Biol Transl Sci 2016;138: 193–211.

Press M. Growth hormone and metabolism. Diabetes Metab Rev 1988;4(4): 391–414.

Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 2012;167(1): 67–74.

Takahashi Y. The role of growth hormone and insulin-like growth factor-I in the liver. Int J Mol Sci 2017;18(7).

Matsumoto R, Fukuoka H, Iguchi G, et al. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency. Growth Hormone IGF Res 2014;24(5): 174–9.

Xu L, Xu C, Yu C, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One 2012;7(8): e44136.

Bergan-Roller HE, Sheridan MA. The growth hormone signaling system: insights into coordinating the anabolic and catabolic actions of growth hormone. Gen Comp Endocrinol 2018;258: 119–33.

Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 2007;1(2): 287–94.

Zaouali MA, Padrissa-Altes S, Ben MI, et al. Insulin like growth factor-1 increases fatty liver preservation in IGL-1 solution. World J Gastroenterol 2010;16(45): 5693–700.

Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci 2018;19(5).

Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017;22(3): 145–52.

Dodington DW, Desai HR, Woo M. JAK/STAT - emerging players in metabolism. Trends Endocrinol Metab 2018;29(1): 55–65.

Qiu H, Yang JK, Chen C. Influence of insulin on growth hormone secretion, level and growth hormone signalling. Sheng Li Xue Bao 2017;69(5): 541–56.

Marechal L, Laviolette M, Rodrigue-Way A, et al. The CD36-PPARgamma pathway in metabolic disorders. Int J Mol Sci 2018;19(5).

Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res 2014;53: 124–44.

Skat-Rordam J, Hojland ID, Lykkesfeldt J, et al. A role of peroxisome proliferatoractivated receptor gamma in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol 2019;124(5): 528–37.

Pepino MY, Kuda O, Samovski D, et al. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr 2014;34: 281–303.

Cai L, Wang Z, Ji A, et al. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity. PLoS One 2012;7(5): e36785.

Hajri T, Han XX, Bonen A, et al. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 2002;109(10): 1381–9.

Kotzka J, Knebel B, Avci H, et al. Phosphorylation of sterol regulatory elementbinding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. Atherosclerosis 2010;213(1): 156–65.

Shen L, Cui A, Xue Y, et al. Hepatic differentiated embryo-chondrocyte-expressed gene 1 (Dec1) inhibits sterol regulatory element-binding protein-1c (Srebp-1c) expression and alleviates fatty liver phenotype. J Biol Chem 2014;289(34): 23332–42.

Smith TM, Gilliland K, Clawson GA, et al. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008;128(5): 1286–93.

Belkaid A, Duguay SR, Ouellette RJ, et al. 17beta-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells. BMC Cancer 2015;15: 440.

Shoham Z, Schachter M. Estrogen biosynthesis–regulation, action, remote effects, and value of monitoring in ovarian stimulation cycles. Fertil Steril 1996;65(4): 687–701.

Bienenfeld A, Azarchi S, Lo SK, et al. Androgens in women: androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol 2019;80(6): 1497–506.

Santen RJ, Simpson E. History of estrogen: its purification, structure, synthesis, biologic actions, and clinical implications. Endocrinology 2019;160(3): 605–25.

O'Reilly MW, Reulen RC, Gupta S, et al. ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: longterm follow-up of 519 patients in two large European centres. Clin Endocrinol (Oxf) 2016;85(5): 748–56.

Hagymasi K, Reismann P, Racz K, et al. [Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease]. Orv Hetil 2009;150(48): 2173–81.

Zhu L, Brown WC, Cai Q, et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 2013;62(2): 424–34.

Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015;21(39): 11053–76.

Shen M, Kumar SP, Shi H. Estradiol regulates insulin signaling and inflammation in adipose tissue. Horm Mol Biol Clin Invest 2014;17(2): 99–107.

Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol 2017;1043: 227–56.

Lundholm L, Zang H, Hirschberg AL, et al. Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertil Steril 2008;90(1): 44–8.

Kim DK, Kim YH, Lee JH, et al. Estrogen-related receptor gamma controls sterol regulatory element-binding protein-1c expression and alcoholic fatty liver. Biochim Biophys Acta Mol Cell Biol Lipids 2019;1864(12): 158521.

Santos RS, Frank AP, Fatima LA, et al. Activation of estrogen receptor alpha induces beiging of adipocytes. Mol Metabol 2018;18: 51–9.

Luo S, Hao L, Li X, et al. Adipose tissue-derived stem cells treated with estradiol enhance survival of autologous fat transplants. Tohoku J Exp Med 2013;231(2): 101–10.

Jeong S, Han M, Lee H, et al. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 2004;53(10): 1284–9.

Rettberg JR, Yao J, Brinton RD. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol 2014;35(1): 8–30.

Huang CF, Yang CY, Chan DC, et al. Arsenic exposure and glucose intolerance/ insulin resistance in estrogen-deficient female mice. Environ Health Perspect 2015;123(11): 1138–44.

Suba Z, Kasler M. [Interactions of insulin and estrogen in the regulation of cell proliferation and carcinogenesis]. Orv Hetil 2012;153(4): 125–36.

Lee C, Kim J, Jung Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Cells 2019;8(10).

Polyzos SA, Mousiolis A, Mintziori G, et al. Nonalcoholic fatty liver disease in males with low testosterone concentrations. Diabetes Metab Syndr 2020;14(5): 1571–7.

Jaruvongvanich V, Sanguankeo A, Riangwiwat T, et al. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 2017;16(3): 382–94.

Haider A, Gooren LJ, Padungtod P, et al. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 2010; 118(3): 167–71.

Kim S, Kwon H, Park JH, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol 2012;12: 69.

Volzke H, Aumann N, Krebs A, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 2010;33(1): 45–53.

Woodcock T, Barker P, Daniel S, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: guidelines from the association of anaesthetists, the royal college of physicians and the society for endocrinology UK. Anaesthesia 2020;75(5): 654–63.

Karaca Z, Hacioglu A, Kelestimur F. Neuroendocrine changes after aneurysmal subarachnoid haemorrhage. Pituitary 2019;22(3): 305–21.

Arnadottir M, Dallongeville J, Nilsson-Ehle P, et al. Effects of short-term treatment with corticotropin on the serum apolipoprotein pattern. Scand J Clin Lab Invest 2001;61(4): 301–6.

He X, Xue P, Xu X, et al. Short-term administration of ACTH improves plasma lipid profile and renal function in kidney transplant patients. Transplant Proc 2006; 38(5): 1371–4.

Berg AL, Rafnsson AT, Johannsson M, et al. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins. Metabolism 2006;55(8): 1083–7.

Xu N, Ekstrom U, Nilsson-Ehle P. ACTH decreases the expression and secretion of apolipoprotein B in HepG2 cell cultures. J Biol Chem 2001;276(42): 38680–4.

Skoog M, Berggren-Soderlund M, Nilsson-Ehle P, et al. Lipid synthesis and secretion in HepG2 cells is not affected by ACTH. Lipids Health Dis 2010;9: 48.

Werner B, Annette K, Christoph W. Corticotropin increases the receptor-specific uptake of native low-density lipoprotein (LDL)—but not of oxidized LDL and native or oxidized lipoprotein(a)[LP(a)]—in HEPG2 cells: No evidence for Lp(a) catabolism via the LDL-receptor. Metabolism 1997;46(7).

Shao S, Yao Z, Lu J, et al. Ablation of prolactin receptor increases hepatic triglyceride accumulation. Biochem Biophys Res Commun 2018;498(3): 693–9.

Zhang P, Ge Z, Wang H, et al. Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol 2018;68(6): 1247–55.